Advertisement

Mikrosatellitenanalyse und p53-Mutationsanalyse zur Responseprädiktion bei lokal fortgeschrittenen neoadjuvant therapierten Magenkarzinomen

  • Katja Ott
  • G. Keller
  • H. Vogelsang
  • U. Fink
  • K. Becker
  • H. Höfler
  • J. R. Siewert
Conference paper
Part of the Deutsche Gesellschaft für Chirurgie book series (DTGESCHIR, volume 31)

Abstract

Former published data of our group suggested that a high rate of LOH in the tumors including LOH at chromosome 17p13 might be associated with good clinical response to neoadjuvant cisplatinum-based chemotherapy in gastric cancer [1]. In this study we extended our analysis to evaluate the influence of chromosomal instability and p53-mutation on therapy response.

Pretherapeutic biopsies of 53 patients were studied at 11 microsatellite loci. A peak allele ration < 0.6 was considered as LOH. p53 mutation analysis was performed by DHPLC (denaturating high pressure chromatography) and direct sequencing.

53 patients were included. 49 Patients were resected. 21 were clinical responders. In respect to histopathological response 14 of the 49 resected patients were classified as responders. 3 tumors showed high microsatellite instability and were not included in LOH and FAL analysis. 15 of the 45 informative tumors exhibited LOH at TP 53. There was a strong assosiation of LOH and clinical response (p = 0.014) and histopathological response (p = 0.02). Tumors of 19 patients had p53 mutations. There was no correlation between response and p53 mutation. Patients with high rate of LOH (FAL > 0,25) showed a significant improved survival (59 vs. 22 months; p = 0.008).

Tumors with a high rate of LOH seem to be more sensitive to this type of therapy. In respect to p53 mutation no association was found.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Grundei T, Vogelsang H, Ott K, Mueller J, Scholz M, Becker K, Fink U, Siewert JR, Höfler H, Keller G (2000) Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma. Clin Cancer Res 6: 4782 - 4788PubMedGoogle Scholar
  2. 2.
    Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA (1999) Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 229: 303 - 308PubMedCrossRefGoogle Scholar
  3. 3.
    Metzger R, Leichmann CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B, Leichman L (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluoruoracil chemotherapy. J Clin Oncol 16: 309–316PubMedGoogle Scholar
  4. 4.
    Uchino S, Noguchi M, Ochiai A, Saito T, Kobayashi M, Hirohashi S (1993) p53 Mutation in gastric Cancer: A genetic model for carcinogenesis is common to gastric cancer and colorectal cancer. Int J Cancer 54: 759 - 764PubMedCrossRefGoogle Scholar
  5. 5.
    Cascinu S, Graziano F, Del Ferro E, Staccioli MP, Ligi M, Carnevali A, Muretto P, Catalano G (1998) Expression of p53 Protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 83: 1917–1922PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • Katja Ott
    • 1
    • 3
  • G. Keller
    • 2
  • H. Vogelsang
    • 1
  • U. Fink
    • 1
  • K. Becker
    • 2
  • H. Höfler
    • 2
  • J. R. Siewert
    • 1
  1. 1.Chirurgische Klinik und PoliklinikGermany
  2. 2.Institut für Pathologie, Klinikum rechts der IsarTechnische UniverstätMünchenGermany
  3. 3.Chirurgische Klinik und Poliklinik, Klinikum rechts der IsarTechnischen Universität MünchenMünchenGermany

Personalised recommendations